RS20050594A - 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis - Google Patents

3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Info

Publication number
RS20050594A
RS20050594A YUP-2005/0594A YUP20050594A RS20050594A RS 20050594 A RS20050594 A RS 20050594A YU P20050594 A YUP20050594 A YU P20050594A RS 20050594 A RS20050594 A RS 20050594A
Authority
RS
Serbia
Prior art keywords
acid derivatives
cyclohexanecarbonyl
ylmethoxy
oxazol
atherosclerosis
Prior art date
Application number
YUP-2005/0594A
Other languages
English (en)
Serbian (sr)
Inventor
Christian Stapper
Dirk Gretzke
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Heiner GLOMBIK
Wolfgang Wendler
Original Assignee
Sanofi-Aventis Deutschalnd Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschalnd Gmbh., filed Critical Sanofi-Aventis Deutschalnd Gmbh.,
Publication of RS20050594A publication Critical patent/RS20050594A/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
YUP-2005/0594A 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis RS20050594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001578 WO2004076426A1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
RS20050594A true RS20050594A (en) 2007-12-31

Family

ID=32920629

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0594A RS20050594A (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Country Status (34)

Country Link
US (5) US7259177B2 (US07259177-20070821-C00218.png)
EP (3) EP1599455B1 (US07259177-20070821-C00218.png)
JP (3) JP2006519199A (US07259177-20070821-C00218.png)
KR (3) KR20050106462A (US07259177-20070821-C00218.png)
CN (3) CN100439347C (US07259177-20070821-C00218.png)
AR (3) AR043427A1 (US07259177-20070821-C00218.png)
AT (3) ATE430738T1 (US07259177-20070821-C00218.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00218.png)
BR (3) BRPI0407758A (US07259177-20070821-C00218.png)
CA (3) CA2517386A1 (US07259177-20070821-C00218.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00218.png)
CO (2) CO5690580A2 (US07259177-20070821-C00218.png)
DE (4) DE10308355A1 (US07259177-20070821-C00218.png)
DK (3) DK1599455T3 (US07259177-20070821-C00218.png)
EC (2) ECSP055986A (US07259177-20070821-C00218.png)
ES (3) ES2287700T3 (US07259177-20070821-C00218.png)
HR (3) HRP20050744A2 (US07259177-20070821-C00218.png)
IL (2) IL170316A (US07259177-20070821-C00218.png)
MA (3) MA27742A1 (US07259177-20070821-C00218.png)
MX (3) MXPA05008988A (US07259177-20070821-C00218.png)
NO (3) NO20054396L (US07259177-20070821-C00218.png)
OA (2) OA13034A (US07259177-20070821-C00218.png)
PA (1) PA8596801A1 (US07259177-20070821-C00218.png)
PE (3) PE20050292A1 (US07259177-20070821-C00218.png)
PL (3) PL378437A1 (US07259177-20070821-C00218.png)
PT (3) PT1599455E (US07259177-20070821-C00218.png)
RS (1) RS20050594A (US07259177-20070821-C00218.png)
RU (3) RU2005129995A (US07259177-20070821-C00218.png)
SA (1) SA04250153A (US07259177-20070821-C00218.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00218.png)
TW (3) TW200500349A (US07259177-20070821-C00218.png)
UY (2) UY28210A1 (US07259177-20070821-C00218.png)
WO (3) WO2004076426A1 (US07259177-20070821-C00218.png)
ZA (2) ZA200505768B (US07259177-20070821-C00218.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
BRPI0621960A2 (pt) 2006-08-10 2011-12-27 Wood One Co Ltd composiÇço hipoglicÊmica contendo derivado da casca de acÁcia
CN105732376A (zh) 2007-08-16 2016-07-06 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
HUE027833T2 (en) * 2008-02-29 2016-11-28 Nissan Chemical Ind Ltd Process for the preparation of a thiophene derivative and its intermediate
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
EP4050422A1 (en) 2017-12-13 2022-08-31 Canon Kabushiki Kaisha Cartridge and image forming apparatus
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
PL327938A1 (en) 1996-01-17 1999-01-04 Novo Nordisk As Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
PT958296E (pt) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
HUP0003999A3 (en) 1997-07-16 2003-03-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AU3275999A (en) * 1998-03-10 1999-09-27 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
JP2003502369A (ja) 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
WO2001004146A2 (en) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
MXPA02000973A (es) 1999-07-29 2002-07-30 Lilly Co Eli Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
CN1372541A (zh) 1999-09-01 2002-10-02 阿文蒂斯药物德国有限公司 磺酰基甲酰胺衍生物、其制备方法及其作为药物的应用
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
HUP0203444A3 (en) 1999-12-03 2003-05-28 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CZ20023234A3 (cs) 2000-03-31 2003-01-15 Probiodrug Ag Léčivo proti diabetu
US6770133B2 (en) 2000-04-25 2004-08-03 Kyorin Pharmaceutical Co., Ltd. Stable crystal of thiazolidinedione derivative and process for producing the same
ES2287120T3 (es) 2000-04-28 2007-12-16 Asahi Kasei Pharma Corporation Nuevos compuestos biciclicos.
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
WO2001094300A1 (de) * 2000-06-09 2001-12-13 Aventis Pharma Deutschland Gmbh Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
SK1872003A3 (en) * 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP4605990B2 (ja) 2000-12-21 2011-01-05 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な1,2−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
KR100718906B1 (ko) * 2000-12-25 2007-05-18 오노 야꾸힝 고교 가부시키가이샤 디히드로나프탈렌 유도체 화합물 및 이 화합물을 유효성분으로 하는 약제
CA2438551A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体(ppar)のモジュレーター
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
PT1425014E (pt) 2001-08-31 2007-03-30 Sanofi Aventis Deutschland Derivados diarilcicloalquilo, processo para a sua preparação como activadores de ppar
US6984661B2 (en) 2002-02-05 2006-01-10 Eli Lilly And Company Urea linker derivatives for use as PPAR modulators
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
TNSN05204A1 (en) 2007-06-11
EP1599452B1 (de) 2007-06-20
TNSN05206A1 (en) 2007-06-11
US7335671B2 (en) 2008-02-26
US7259177B2 (en) 2007-08-21
EP1599453B1 (de) 2009-05-06
KR20050106461A (ko) 2005-11-09
AU2004215677B2 (en) 2010-01-07
CN100439347C (zh) 2008-12-03
KR20050105492A (ko) 2005-11-04
CA2516620A1 (en) 2004-09-10
NO20054398D0 (no) 2005-09-22
ZA200505768B (en) 2005-11-23
ATE430738T1 (de) 2009-05-15
PL377735A1 (pl) 2006-02-20
US20080167354A1 (en) 2008-07-10
OA13034A (en) 2006-11-10
AU2004215677A1 (en) 2004-09-10
CN1753879A (zh) 2006-03-29
EP1599455B1 (de) 2009-07-01
TW200508210A (en) 2005-03-01
NO20054396L (no) 2005-11-11
MXPA05008988A (es) 2005-10-18
HRP20050744A2 (en) 2006-09-30
PT1599452E (pt) 2007-09-12
MA27737A1 (fr) 2006-02-01
HRP20050742A2 (en) 2006-09-30
AR043432A1 (es) 2005-07-27
CN100439345C (zh) 2008-12-03
NO20054396D0 (no) 2005-09-22
CA2517386A1 (en) 2004-09-10
US20050101637A1 (en) 2005-05-12
AU2004215673B2 (en) 2009-10-01
US7365084B2 (en) 2008-04-29
CN1753881A (zh) 2006-03-29
IL170314A (en) 2010-11-30
ES2287700T3 (es) 2007-12-16
AU2004215672A1 (en) 2004-09-10
CL2004000391A1 (es) 2005-01-07
DK1599452T3 (da) 2007-10-01
CO5690578A2 (es) 2006-10-31
JP2006519199A (ja) 2006-08-24
PE20050292A1 (es) 2005-05-24
NO20054398L (no) 2005-11-02
US20040209920A1 (en) 2004-10-21
WO2004076426A1 (de) 2004-09-10
BRPI0407758A (pt) 2006-02-14
MXPA05008951A (es) 2005-11-04
AU2004215672B2 (en) 2010-01-07
ES2329366T3 (es) 2009-11-25
AR043433A1 (es) 2005-07-27
OA13035A (en) 2006-11-10
EP1599455A1 (de) 2005-11-30
CA2517381A1 (en) 2004-09-10
RU2005129992A (ru) 2006-02-10
RU2005129995A (ru) 2006-01-27
EP1599452A1 (de) 2005-11-30
WO2004076427A1 (de) 2004-09-10
DE502004009690D1 (de) 2009-08-13
DE502004009453D1 (de) 2009-06-18
PT1599453E (pt) 2009-07-14
MA27742A1 (fr) 2006-02-01
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
PE20050293A1 (es) 2005-05-24
US20080015238A1 (en) 2008-01-17
DK1599455T3 (da) 2009-11-09
BRPI0407814A (pt) 2006-02-14
DE502004004139D1 (de) 2007-08-02
PE20040959A1 (es) 2005-01-17
PL378437A1 (pl) 2006-04-03
US7872034B2 (en) 2011-01-18
CN100398526C (zh) 2008-07-02
KR20050106462A (ko) 2005-11-09
AU2004215673A1 (en) 2004-09-10
DE10308355A1 (de) 2004-12-23
JP2006519194A (ja) 2006-08-24
JP2006519193A (ja) 2006-08-24
TW200510352A (en) 2005-03-16
TW200500349A (en) 2005-01-01
MA27736A1 (fr) 2006-02-01
RU2005130002A (ru) 2006-01-27
UY28210A1 (es) 2004-09-30
AR043427A1 (es) 2005-07-27
CL2004000392A1 (es) 2005-04-22
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
PT1599455E (pt) 2009-09-29
ECSP055986A (es) 2006-01-16
CO5690580A2 (es) 2006-10-31
EP1599453A1 (de) 2005-11-30
US20050215596A1 (en) 2005-09-29
PL378130A1 (pl) 2006-03-06
MXPA05008995A (es) 2005-10-18
NO20054408D0 (no) 2005-09-22
BRPI0407907A (pt) 2006-02-14
ZA200505765B (en) 2006-05-31
ES2326418T3 (es) 2009-10-09
ATE435217T1 (de) 2009-07-15
ATE365159T1 (de) 2007-07-15
SA04250153A (ar) 2005-12-03
DK1599453T3 (da) 2009-08-24
WO2004076428A1 (de) 2004-09-10
ECSP055985A (es) 2006-01-16
UY28209A1 (es) 2004-09-30
CN1756748A (zh) 2006-04-05

Similar Documents

Publication Publication Date Title
TNSN05206A1 (en) 3-methyl-2-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
RS20050019A (en) Heterocyclically substituted benzoylureas,method for their production and their use as medicaments
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
MXPA04001850A (es) Derivados de diarilcicloalquilo, procedimientos para su preparacion y su utilizacion como agentes activadores de ppar.
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
HK1076815A1 (en) 1,2,3-trisubstitued aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such asdiabetes and hyperglycemia
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
TNSN06005A1 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
AU2003219107A1 (en) Tuberculosis treatment using pleuromutilin derivatives
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MXPA05008993A (es) Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos.
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
HRP20050667A2 (en) Corbonyl-amino substituted acyl phenyl urea derivatives, method for the production and use thereof
WO2008023004A8 (de) Enantiomerenreine betaagonisten, verfahren zu deren herstellungen und deren verwendung als arzneimittel
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
MXPA05008990A (es) Derivados de acido alcanoico sustituido con cicloalquilo, metodos para su produccion y su uso como medicamentos.
UA92450C2 (ru) 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
MXPA05009054A (es) Derivados de arilcicloalquilo con cadenas laterales ramificadas en calidad de moduladores de receptores ppar, metodo para su produccion y su uso como medicamentos.
TNSN05205A1 (en) Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament
WO2004033416A3 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel